H.C. Wainwright raised the price target for the iTeos Therapeutics Inc. (NASDAQ:ITOS) stock to “a Buy”. The rating was released on May 05, 2021, according to finviz. The research report from Wedbush has initiated the stock to Outperform, with a price target set at $45. The stock was initiated by SVB Leerink, who disclosed in a research note on August 18, 2020, to Outperform and set the price objective to $45. In their research brief published August 18, 2020, Piper Sandler analysts initiated the iTeos Therapeutics Inc. stock to Overweight with a price target of $50.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of iTeos Therapeutics Inc. (NASDAQ:ITOS) dipped -4.40% to close Friday’s market session at $14.12, lower as compared to yesterday’s close. The stock price fluctuated between $13.81 and $14.77 throughout the trading session with the volume trading being 942746 shares, which represented a significant variation when compared to the three months average volume of 285.60K shares. The firm’s stock price fluctuated -12.19% within the last five trades and -23.84% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -30.44% in the last 6 months and -33.27% was subtracted to its value over the previous 3 months. ITOS stock is trading at a margin of -17.27%, -25.06% and -30.97% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
As of the close of trading, ITOS deals in the Healthcare domain. The stock is trading -62.10 percent below its 52-week high and -3.68 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -58.37. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does iTeos Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 71.00 percent and the profit margin is 57.50 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $520.46 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for iTeos Therapeutics Inc. (NASDAQ:ITOS) is 2.07. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 1.15 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 0.79, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Hallal David, the Director at iTeos Therapeutics Inc. (ITOS) has sold 1,171 shares of firm on Jun 09 at a price of $19.51 against the total amount of $22846.0. In another inside trade, Hallal David, Director of iTeos Therapeutics Inc. (NASDAQ:ITOS) sold 28,444 shares of the firm on Jun 08 for a total worth of $0.57 million at a price of $20.19. An inside trade which took place on May 11, Director of iTeos Therapeutics Inc. Davis Aaron I. sold 338,000 shares of firm against total price of $6.17 million at the cost of $18.25 per share.